No data available for drug.
DRUG INTERACTION
No drug interaction found for ethinylestradiol and .
pegaspargase
They may increase the thrombogenic effect when combined with asparaginase Products
phenobarbital
may decrease the levels of serum concentration of hormonal contraceptives
isoniazid
may decrease the levels of serum concentration of hormonal contraceptives
propofol
may decrease the levels of serum concentration of hormonal contraceptives
selexipag
may decrease the levels of serum concentration of hormonal contraceptives
carbamazepine
may decrease the levels of serum concentration of hormonal contraceptives
amprenavir
may decrease the levels of serum concentration of hormonal contraceptives
fostemsavir
may decrease the levels of serum concentration of hormonal contraceptives
indinavir
may decrease the levels of serum concentration of hormonal contraceptives
tranexamic acid
may increase the toxicity of each other through pharmacodynamic synergism
tirzepatide
may reduce the levels of serum concentration of hormonal contraceptives
aprepitant
aprepitant: they may diminish the serum concentration of hormonal contraceptives
asunaprevir
asunaprevir: they may diminish the serum concentration of hormonal contraceptives
atazanavir
atazanavir: they may diminish the serum concentration of hormonal contraceptives
brigatinib
brigatinib: they may diminish the serum concentration of hormonal contraceptives
carfilzomib
carfilzomib: they may increase the thrombogenic effect of hormonal contraceptives
cladribine
cladribine: they may decrease the therapeutic effect of hormonal contraceptives
cobicistat
cobicistat: they may diminish the serum concentration of hormonal contraceptives
efavirenz
efavirenz: they may diminish the serum concentration of hormonal contraceptives
elagolix
elagolix: they may diminish the therapeutic effect of hormonal contraceptives
exenatide
exenatide: they may diminish the therapeutic effect of hormonal contraceptives
felbamate
felbamate: they may diminish the serum concentration of hormonal contraceptives
fosaprepitant
fosaprepitant: they may diminish the serum concentration of hormonal contraceptives
griseofulvin
griseofulvin: they may diminish the serum concentration of hormonal contraceptives
ivosidenib
ivosidenib: they may diminish the serum concentration of hormonal contraceptives
ixazomib
ixazomib: they may diminish the serum concentration of hormonal contraceptives
lixisenatide
lixisenatide: they may decrease the therapeutic effect of hormonal contraceptives
mavacamten
mavacamten: they may diminish the serum concentration of hormonal contraceptives
mifepristone
mifepristone: they may decrease the therapeutic effect of hormonal contraceptives
mycophenolate mofetil
mycophenolate mofetil: they may diminish the serum concentration of hormonal contraceptives
nirmatrelvir/ritonavir
nirmatrelvir and ritonavir: they may diminish the serum concentration of hormonal contraceptives
oxcarbazepine
oxcarbazepine: they may diminish the serum concentration of hormonal contraceptives
pitolisant
pitolisant: they may diminish the serum concentration of hormonal contraceptives
nelfinavir
protease inhibitors: they may diminish the serum concentration of hormonal contraceptives
tazemetostat
tazemetostat: they may diminish the serum concentration of hormonal contraceptives
cannabidiol
cannabidiol: they may diminish the serum concentration of hormonal contraceptives
sotorasib
may diminish the serum concentration of CYP3A4 Inducers
etonogestrel
may diminish the serum concentration of each other when combined
eptinezumab
it increases the adverse effects caused due to eptinezumab
ofatumumab
in combination with ofatumumab, they increase the activity of thrombogenesis
encorafenib
encorafenib: they may diminish the serum concentration of hormonal contraceptives
mobocertinib
mobocertinib: they may diminish the serum concentration of hormonal contraceptives
omaveloxolone
omaveloxolone: they may diminish the serum concentration of hormonal contraceptives
pexidartinib
pexidartinib: they may diminish the serum cocentration of hormonal contraceptives
tranexamic acid
tranexamic acid: they may increase the thrombogenic effect of hormonal contraceptives
acenocoumarol
may increase the serum concentration of Vitamin K Antagonists
fluindione
may increase the serum concentration of Vitamin K Antagonists
phenindione
may increase the serum concentration of Vitamin K Antagonists
phylloquinone
may increase the serum concentration of Vitamin K Antagonists
warfarin
may increase the serum concentration of Vitamin K Antagonists
acenocoumarol
may increase the levels of serum concentration of vitamin K antagonists
fluindione
may increase the levels of serum concentration of vitamin K antagonists
phenindione
may increase the levels of serum concentration of vitamin K antagonists
phylloquinone
may increase the levels of serum concentration of vitamin K antagonists
warfarin
may increase the levels of serum concentration of vitamin K antagonists
lenacapavir
may increase the levels of serum concentration
abiraterone
may increase the levels of serum concentration
mibefradil
may increase the levels of serum concentration
citalopram
may increase the levels of serum concentration
efavirenz
may increase the levels of serum concentration
maralixibat
may increase the levels of serum concentration
lenacapavir
may increase the levels of serum concentration
curcumin
may increase the levels of serum concentration
glecaprevir
may increase the levels of serum concentration
caspofungin
may increase the levels of serum concentration
maralixibat
may increase the levels of serum concentration
lenacapavir
may increase the levels of serum concentration
diacerein
may increase the levels of serum concentration
metformin
It may diminish the effects when combined with metformin by pharmacodynamic antagonism
diosmin
it may diminish the metabolism when combined with diosmin
pranlukast
Combining ethinylestradiol with pranlukast may cause a reduction in the ethinylestradiol’s metabolism
bromazepam
when bromazepam and ethinylestradiol are used together, there is a potential reduction in the bromazepam's metabolism
lorlatinib
the effect of ethinylestradiol is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
romidepsin
when both drugs are combined, there may be a decreased effects of ethinylestradiol by receptor binding competition
cefadroxil
when both drugs are combined, there may be a decreased effect of ethinylestradiol by altering intestinal flora
cefotaxime
when both drugs are combined, there may be a decreased effect of ethinylestradiol by altering intestinal flora
demeclocycline
demeclocycline may interfere with the intestinal flora and reduce the effects of conjugated estrogens (oral form of hormones)
doxycycline
doxycycline may interfere with the intestinal flora and reduce the effects of conjugated estrogens (oral form of hormones)
amoxicillin vonoprazan
when both drugs are combined, there may be a decreased effect of the drug's action by decreasing renal clearance
carfilzomib
protease inhibitors may reduce the level of serum concentration of hormonal contraceptives
ritonavir
protease inhibitors may reduce the level of serum concentration of hormonal contraceptives
simeprevir
protease inhibitors may reduce the level of serum concentration of hormonal contraceptives
bortezomib
protease inhibitors may reduce the level of serum concentration of hormonal contraceptives
fosamprenavir
protease inhibitors may reduce the level of serum concentration of hormonal contraceptives
efavirenz
CYP3A4 Inducers may decrease the levels of serum concentration of hormonal contraceptives
diacerein
may decrease the levels of serum concentration of hormonal contraceptives
tranylcypromine
may decrease the levels of serum concentration of hormonal contraceptives
anastrozole
may decrease the levels of serum concentration of hormonal contraceptives
lenacapavir
may increase the levels of serum concentration of hormonal contraceptives
abiraterone
may increase the levels of serum concentration of hormonal contraceptives
mibefradil
may increase the levels of serum concentration of hormonal contraceptives
isoniazid
may increase the levels of serum concentration of hormonal contraceptives
mexiletine
may increase the levels of serum concentration of hormonal contraceptives
lenacapavir
may increase the levels of serum concentration of hormonal contraceptives
curcumin
may increase the levels of serum concentration of hormonal contraceptives
glecaprevir
may increase the levels of serum concentration of hormonal contraceptives
caspofungin
may increase the levels of serum concentration of hormonal contraceptives
abiraterone
may increase the levels of serum concentration of hormonal contraceptives
primidone
may decrease the levels of serum concentration
citalopram
may increase the levels of serum concentration
efavirenz
may increase the levels of serum concentration
maralixibat
may decrease the levels of serum concentration
maralixibat
may increase the levels of serum concentration
lenacapavir
may increase the levels of serum concentration
sotrovimab
It may enhance the thrombogenic activities when combined with sotrovimab
etravirine
etravirine: they may diminish the serum concentration of hormonal contraceptive
flibanserin
flibanserin: they may enhance the serum concentration of hormonal contraceptives
thalidomide
thalidomide: they may increase the thrombogenic effect of hormonal contraceptives
voriconazole
voriconazole: they may enhance the serum concentration of hormonal contraceptives
lixisenatide
It may diminish the effect when combined with lixisenatide by inhibiting gastrointestinal absorption
primidone
CYP3A4 inducers decrease the concentration of hormonal contraceptives in the serum
phenobarbital
CYP3A4 inducers decrease the concentration of hormonal contraceptives in the serum
carbamazepine
CYP3A4 inducers decrease the concentration of hormonal contraceptives in the serum
efavirenz
CYP3A4 inducers decrease the concentration of hormonal contraceptives in the serum
isoniazid
CYP3A4 inducers decrease the concentration of hormonal contraceptives in the serum
topiramate
topiramate decreases the concentration of hormonal contraceptives in the serum
perampanel
perampanel decreases the concentration of hormonal contraceptives in the serum
No data available for drug.
DRUG INTERACTION
ethinylestradiol
&
No Drug Intearction Found. for ethinylestradiol and .
pegaspargase
They may increase the thrombogenic effect when combined with asparaginase Products
phenobarbital
may decrease the levels of serum concentration of hormonal contraceptives
isoniazid
may decrease the levels of serum concentration of hormonal contraceptives
propofol
may decrease the levels of serum concentration of hormonal contraceptives
selexipag
may decrease the levels of serum concentration of hormonal contraceptives
carbamazepine
may decrease the levels of serum concentration of hormonal contraceptives
amprenavir
may decrease the levels of serum concentration of hormonal contraceptives
fostemsavir
may decrease the levels of serum concentration of hormonal contraceptives
indinavir
may decrease the levels of serum concentration of hormonal contraceptives
tranexamic acid
may increase the toxicity of each other through pharmacodynamic synergism
tirzepatide
may reduce the levels of serum concentration of hormonal contraceptives
aprepitant
aprepitant: they may diminish the serum concentration of hormonal contraceptives
asunaprevir
asunaprevir: they may diminish the serum concentration of hormonal contraceptives
atazanavir
atazanavir: they may diminish the serum concentration of hormonal contraceptives
brigatinib
brigatinib: they may diminish the serum concentration of hormonal contraceptives
carfilzomib
carfilzomib: they may increase the thrombogenic effect of hormonal contraceptives
cladribine
cladribine: they may decrease the therapeutic effect of hormonal contraceptives
cobicistat
cobicistat: they may diminish the serum concentration of hormonal contraceptives
efavirenz
efavirenz: they may diminish the serum concentration of hormonal contraceptives
elagolix
elagolix: they may diminish the therapeutic effect of hormonal contraceptives
exenatide
exenatide: they may diminish the therapeutic effect of hormonal contraceptives
felbamate
felbamate: they may diminish the serum concentration of hormonal contraceptives
fosaprepitant
fosaprepitant: they may diminish the serum concentration of hormonal contraceptives
griseofulvin
griseofulvin: they may diminish the serum concentration of hormonal contraceptives
ivosidenib
ivosidenib: they may diminish the serum concentration of hormonal contraceptives
ixazomib
ixazomib: they may diminish the serum concentration of hormonal contraceptives
lixisenatide
lixisenatide: they may decrease the therapeutic effect of hormonal contraceptives
mavacamten
mavacamten: they may diminish the serum concentration of hormonal contraceptives
mifepristone
mifepristone: they may decrease the therapeutic effect of hormonal contraceptives
mycophenolate mofetil
mycophenolate mofetil: they may diminish the serum concentration of hormonal contraceptives
nirmatrelvir/ritonavir
nirmatrelvir and ritonavir: they may diminish the serum concentration of hormonal contraceptives
oxcarbazepine
oxcarbazepine: they may diminish the serum concentration of hormonal contraceptives
pitolisant
pitolisant: they may diminish the serum concentration of hormonal contraceptives
nelfinavir
protease inhibitors: they may diminish the serum concentration of hormonal contraceptives
tazemetostat
tazemetostat: they may diminish the serum concentration of hormonal contraceptives
cannabidiol
cannabidiol: they may diminish the serum concentration of hormonal contraceptives
sotorasib
may diminish the serum concentration of CYP3A4 Inducers
etonogestrel
may diminish the serum concentration of each other when combined
eptinezumab
it increases the adverse effects caused due to eptinezumab
ofatumumab
in combination with ofatumumab, they increase the activity of thrombogenesis
encorafenib
encorafenib: they may diminish the serum concentration of hormonal contraceptives
mobocertinib
mobocertinib: they may diminish the serum concentration of hormonal contraceptives
omaveloxolone
omaveloxolone: they may diminish the serum concentration of hormonal contraceptives
pexidartinib
pexidartinib: they may diminish the serum cocentration of hormonal contraceptives
tranexamic acid
tranexamic acid: they may increase the thrombogenic effect of hormonal contraceptives
acenocoumarol
may increase the serum concentration of Vitamin K Antagonists
fluindione
may increase the serum concentration of Vitamin K Antagonists
phenindione
may increase the serum concentration of Vitamin K Antagonists
phylloquinone
may increase the serum concentration of Vitamin K Antagonists
warfarin
may increase the serum concentration of Vitamin K Antagonists
acenocoumarol
may increase the levels of serum concentration of vitamin K antagonists
fluindione
may increase the levels of serum concentration of vitamin K antagonists
phenindione
may increase the levels of serum concentration of vitamin K antagonists
phylloquinone
may increase the levels of serum concentration of vitamin K antagonists
warfarin
may increase the levels of serum concentration of vitamin K antagonists
lenacapavir
may increase the levels of serum concentration
abiraterone
may increase the levels of serum concentration
mibefradil
may increase the levels of serum concentration
citalopram
may increase the levels of serum concentration
efavirenz
may increase the levels of serum concentration
maralixibat
may increase the levels of serum concentration
lenacapavir
may increase the levels of serum concentration
curcumin
may increase the levels of serum concentration
glecaprevir
may increase the levels of serum concentration
caspofungin
may increase the levels of serum concentration
maralixibat
may increase the levels of serum concentration
lenacapavir
may increase the levels of serum concentration
diacerein
may increase the levels of serum concentration
metformin
It may diminish the effects when combined with metformin by pharmacodynamic antagonism
diosmin
it may diminish the metabolism when combined with diosmin
pranlukast
Combining ethinylestradiol with pranlukast may cause a reduction in the ethinylestradiol’s metabolism
bromazepam
when bromazepam and ethinylestradiol are used together, there is a potential reduction in the bromazepam's metabolism
lorlatinib
the effect of ethinylestradiol is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
romidepsin
when both drugs are combined, there may be a decreased effects of ethinylestradiol by receptor binding competition
cefadroxil
when both drugs are combined, there may be a decreased effect of ethinylestradiol by altering intestinal flora
cefotaxime
when both drugs are combined, there may be a decreased effect of ethinylestradiol by altering intestinal flora
demeclocycline
demeclocycline may interfere with the intestinal flora and reduce the effects of conjugated estrogens (oral form of hormones)
doxycycline
doxycycline may interfere with the intestinal flora and reduce the effects of conjugated estrogens (oral form of hormones)
amoxicillin vonoprazan
when both drugs are combined, there may be a decreased effect of the drug's action by decreasing renal clearance
carfilzomib
protease inhibitors may reduce the level of serum concentration of hormonal contraceptives
ritonavir
protease inhibitors may reduce the level of serum concentration of hormonal contraceptives
simeprevir
protease inhibitors may reduce the level of serum concentration of hormonal contraceptives
bortezomib
protease inhibitors may reduce the level of serum concentration of hormonal contraceptives
fosamprenavir
protease inhibitors may reduce the level of serum concentration of hormonal contraceptives
efavirenz
CYP3A4 Inducers may decrease the levels of serum concentration of hormonal contraceptives
diacerein
may decrease the levels of serum concentration of hormonal contraceptives
tranylcypromine
may decrease the levels of serum concentration of hormonal contraceptives
anastrozole
may decrease the levels of serum concentration of hormonal contraceptives
lenacapavir
may increase the levels of serum concentration of hormonal contraceptives
abiraterone
may increase the levels of serum concentration of hormonal contraceptives
mibefradil
may increase the levels of serum concentration of hormonal contraceptives
isoniazid
may increase the levels of serum concentration of hormonal contraceptives
mexiletine
may increase the levels of serum concentration of hormonal contraceptives
lenacapavir
may increase the levels of serum concentration of hormonal contraceptives
curcumin
may increase the levels of serum concentration of hormonal contraceptives
glecaprevir
may increase the levels of serum concentration of hormonal contraceptives
caspofungin
may increase the levels of serum concentration of hormonal contraceptives
abiraterone
may increase the levels of serum concentration of hormonal contraceptives
primidone
may decrease the levels of serum concentration
citalopram
may increase the levels of serum concentration
efavirenz
may increase the levels of serum concentration
maralixibat
may decrease the levels of serum concentration
maralixibat
may increase the levels of serum concentration
lenacapavir
may increase the levels of serum concentration
sotrovimab
It may enhance the thrombogenic activities when combined with sotrovimab
etravirine
etravirine: they may diminish the serum concentration of hormonal contraceptive
flibanserin
flibanserin: they may enhance the serum concentration of hormonal contraceptives
thalidomide
thalidomide: they may increase the thrombogenic effect of hormonal contraceptives
voriconazole
voriconazole: they may enhance the serum concentration of hormonal contraceptives
lixisenatide
It may diminish the effect when combined with lixisenatide by inhibiting gastrointestinal absorption
primidone
CYP3A4 inducers decrease the concentration of hormonal contraceptives in the serum
phenobarbital
CYP3A4 inducers decrease the concentration of hormonal contraceptives in the serum
carbamazepine
CYP3A4 inducers decrease the concentration of hormonal contraceptives in the serum
efavirenz
CYP3A4 inducers decrease the concentration of hormonal contraceptives in the serum
isoniazid
CYP3A4 inducers decrease the concentration of hormonal contraceptives in the serum
topiramate
topiramate decreases the concentration of hormonal contraceptives in the serum
perampanel
perampanel decreases the concentration of hormonal contraceptives in the serum